Finerenone in Patients with Focal Segmental Glomerulosclerosis

Background: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). Methods: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m 2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m 2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). Results: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m 2 , and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m 2 /year (95% CI, 0.5–2.2; P =0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m 2 /year), and among participants with primary or secondary FSGS ( P -interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30–1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%–53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0–17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. Conclusions: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2026-11-15
DOI
https://doi.org/10.1681/asn.0000001333
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Finerenone in Patients with Focal Segmental Glomerulosclerosis

Susanne B. Nicholas, Jürgen Floege, Brendon Lange Neuen, Mario Berger et al.
Journal of the American Society of Nephrology
Renal Diseases and Glomerulopathies
article

Finerenone in Patients with Focal Segmental Glomerulosclerosis

Susanne B. Nicholas, Jürgen Floege, Brendon Lange Neuen, Mario Berger, Niels Jongs, Marijn M. Speeckaert, Pantelis A. Sarafidis, David Z.I. Cherney, Hiddo J.L. Heerspink, Christoph Wanner, Alfredo Chew‐Wong, Glenn Matthew Chertow, Pablo E. Pérgola, Katherine R. Tuttle, Patrick Schloemer, MEIKE DANIELA BRINKER, Jonathan Barratt, Hirokazu Okada, Tim Friede, Vladimir Dobronravov, Rania Dayoub, Johannes David Smeijer, Aidan MacNamara, Carolina Aldworth, Carolyn S.P. Lam, David Packham, Rajiv Agarwal, 汤水福, Vlado Perkovic, Marina Yael Finkelsztein, for the FIND-CKD Investigators
article en

Abstract

Background: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). Methods: The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m 2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m 2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). Results: Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m 2 , and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m 2 /year (95% CI, 0.5–2.2; P =0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m 2 /year), and among participants with primary or secondary FSGS ( P -interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30–1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%–53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0–17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. Conclusions: Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.

Journal of the American Society of Nephrology
Guangzhou University of Chinese Medicine (CN), The Royal Melbourne Hospital (AU), University Health Network (CA), University Medical Center Groningen (NL), Bayer (United States) (US), University of Leicester (GB), University of California, Los Angeles (US), National University of Singapore (SG), University of Groningen (NL), University of Toronto (CA), University of Washington (US), Aristotle University of Thessaloniki (GR), University of Würzburg (DE), First Pavlov State Medical University of St. Petersburg (RU), Royal North Shore Hospital (AU), Leicester General Hospital (GB), Toronto General Hospital (CA), University Hospital Regensburg (DE), UNSW Sydney (AU), Ghent University (BE), Richard L. Roudebush VA Medical Center (US), The George Institute for Global Health (AU), Ippokrateio General Hospital of Thessaloniki (GR), Universitätsmedizin Göttingen (DE), Universitätsklinikum Aachen (DE), Duke-NUS Medical School (SG), Stanford Medicine (US), National Heart Centre Singapore (SG), Renal Associates P. A. (US), Indiana University School of Medicine (US), Bayer (Germany) (DE), Saitama Medical University (JP), Stanford University (US)
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon